• Advanced Myeloma Patients Responding to Selinexor Plus Standard Therapies in Trial, Data Show
  • Trillium Doses First Patient with TTI-622, a Candidate for Treating Myeloma, Lymphoma
  • Companies Collaborating to Use ClonoSEQ Assay in Multiple Myeloma Trials Testing Isatuximab
  • Clinical Trial of Potential CAR T-cell Therapy for Advanced Multiple Myeloma to Open in US
  • Amgen, MD Anderson Collaborate to Advance Early-stage Treatments for Myeloma, Other Cancers
  • Aplidin-Dexamethasone Combo Improves Survival in Advanced Multiple Myeloma Patients, Phase 3 Trial Reports
  • Most in U.S. are Unaware of Recent Shortages of Cancer Therapies, Survey Says
  • Tilsotolimod and Yervoy Combo Seen to Shrink Tumors in Pre-treated Metastatic Melanoma Patients in Ongoing Phase 2 Trial
  • Pomalyst Triple Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients, Phase 3 Data Show
  • Janssen Halts Clinical Trials of Darzalex with PD-1/PD-L1 Inhibitors Amid Concerns Over Safety, Effectiveness
  • Trial Data Supports Darzalex Combo as Potentially Effective in Myeloma Patients Who Don’t Respond to Revlimid
  • Canadian Researchers Launch Study to Make Stem Cell Transplants Safer, More Efficient